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Background/aim: Rheumatoid arthritis (RA) is the most extensive inflammatory arthritis causing permanent deformities in the joint.
Increasing evidence suggests that oxidative stress is a substantial factor in the pathogenesis of RA. This study aimed to examine the
salivary oxidant-antioxidant status of RA and control groups and to compare these biomarkers by correlating them with disease activity,
acute phase reactants, and clinical findings.
Materials and methods: Age and sex-matched 60 participants including 30 patients with RA and 30 control (50 females, 10 males;
mean age: 42.62 ± 10.89 years) were evaluated. RA disease activity and severity were evaluated by the disease activity score 28-C
reactive protein (DAS 28-CRP). Rheumatoid factor (RF) positivity, anticitrullinated protein antibodies (ACPA) positivity, erythrocyte
sedimentation rate (ESR), CRP, tender and swollen joint counts, and medical treatment regimens of the patients (glucocorticoids,
conventional or biologic disease-modifying antirheumatic drugs) were recorded. In the radiographic examination, dental findings, and
bone alterations of the temporomandibular joint (TMJ) were recorded and compared for both groups. Saliva samples were obtained for
analysis of total antioxidant status (TAS), total oxidant status (TOS), arylesterase (ARE), and oxidative stress index (OSI) levels. The data
analysis was conducted by independent sample t-test and chi-square test.
Results: Condylar erosion was the most common radiographic change in TMJ of RA patients. Osteophyte formation was a prominent
finding in the control group. Lower TAS and higher OSI levels were found in RA patients compared with controls (p = 0.013; p = 0.029,
respectively). The effect of DAS 28-CRP score on the levels of oxidative stress biomarkers in RA patients was not significant.
Conclusion: Oxidative stress causes tissue damage in response to excessive mechanical loading, which in turn promotes TMD. However,
disease activity has not a prominent impact on the salivary oxidative stress status of RA patients.
Key words: Oxidative stress, rheumatoid arthritis, saliva, temporomandibular joint disorders

1. Introduction
Rheumatoid arthritis (RA) is a progressive, inflammatory
and autoimmune disease and makes unfavourable changes
in joint structures such as cartilage, tendons, and synovium.
These changes lead to chronic pain, tissue edema, motility
limitations, decreased health quality/functionality, and
accelerated aging. RA can affect many visceral organs
or systems too. The major oral cavity findings of RA are
progressive tooth loss, xerostomia, and mild to severe
temporomandibular joint disorders (TMD) [1,2]. In RA
patients with TMD, pain, swelling, crepitation of the
joint, and limitation of the mouth opening result from a
vicious circle of inflammation [3]. TMD was observed in

more than 66% of RA patients, and otalgia, pain in the
temporomandibular joint, crepitation, and tinnitus were
among the accompanying symptoms [4]. Radiographic
findings include erosion and flattening of the condylar
head and narrowing of the joint space [5].
Although the exact pathology of RA is not known, it
has been stated that unbalanced immune activity triggers
reactive oxygen species (ROS) production leading to
oxidative stress-related microenvironment development in
the tissues [6,7]. Indeed, previous studies have shown that
lower antioxidant capacity and dense lipid peroxidation
metabolites in the serum and synovial fluid were
predominant risk factors in the pathogenesis of RA [8,9].
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Saliva is known as the first antioxidative barrier
against oxidative stress [10]. Many enzyme systems such
as superoxide dismutase, catalase, glutathione peroxidase
constitute the enzymatic protection against ROS [11].
Although there are lots of reports showing functional
changes of these antioxidants separately, measuring all
of these antioxidants one by one is both time-consuming
process and not practical. Therefore, for obvious
antioxidant-oxidant homeostasis, total antioxidant status
(TAS), total oxidant status (TOS), and oxidative stress
index (OSI) which is the ratio of TOS to TAS levels are
focuses of current many clinical trials. Unbalanced
oxidative stress consumes TAS leading to a low OSI index
value [12].
Regarding the salivary antioxidants, arylesterase (ARE)
requires special attention because the variable activities of
ARE are also associated with antioxidative properties [13].
This protein is involved in the oxidation process of lipids
and glycose metabolites and is effective in the control
of various inflammatory and autoimmune pathways in
diseases such as RA [14].
To our knowledge, the change in salivary total oxidant/
antioxidant status (TOS/TAS/OSI) and ARE activity in RA
patients with TMD and controls has not been studied. In
line with this, we aimed to investigate the salivary oxidantantioxidant status of RA and control groups and compare
these biomarkers by correlating them with disease activity,
acute phase reactants, and clinical findings.
2. Materials and methods
2.1. Study population
This cross-sectional research was approved by the local
ethics committee (No: 449/2020), and all participants
signed a consent form before the start of the study. The
study sample consisted of 30 patients recruited randomly
in three months (November 2020-January 2021), who are
in follow-up at the Bolu Abant İzzet Baysal University,
Department of Rheumatology and have symptoms
associated with TMD (the feeling of muscular tension or
stiffness during the day, masseter, and/or temporal muscle
and TMJ pain, restricted mouth opening, and TMJ noises
while jaw movement). The age and sex-matched control
group were randomly selected among healthy individuals
diagnosed with TMD in the Oral and Maxillofacial
Surgery Department. Patients with a history of trauma
in the maxillofacial region, pregnancy, smoking/alcohol
consumption, and antioxidant supplements intake were
excluded from the study.
2.2. Clinical assessment
Patients diagnosed with RA according to the 2010 ACR/
EULAR classification criteria were included in the study
[15]. All of the patients passed on a physical examination.
Medical history, drugs, and symptom interrogation
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were made. Laboratory tests were examined in fasting
blood samples. Erythrocyte sedimentation rate (ESR)
was assigned using the Westergren technique and C
reactive protein (CRP) was determined by nephelometry.
Serum rheumatoid factor (RF) was evaluated by the latex
agglutination technique. The positivity of antibodies
against the cyclic citrullinated peptide (anti-CCP) in
serum was determined using the Diastat kit (Axis-Shield
Diagnostics, Dundee, UK) with a cut-off value of 5 U/mL.
Patients were considered seropositive if any or both of RF or
anti-CCP antibodies were positive. At the time of the study,
28 patients were using at least one conventional diseasemodifying antirheumatic drugs (csDMARDs) or biologic
DMARDs (bDMARDs). Patients were using methotrexate,
sulfasalazine, leflunomide, and hydroxychloroquine as
csDMARDs. Infliximab and adalimumab were bDMARDs
that patients were using. Twenty-one patients (70%) were
using glucocorticoids (GC). The mean GC dosage was 3.3
mg/day prednisolone equivalent. Twenty-seven patients
were using csDMARDs and six were on bDMARDs. The
patients using high doses of GC (>10 mg/day prednisolone
equivalent) were excluded from the study to exclude the
possible role of GCs enhancing oxidative stress. Disease
activity score 28-CRP (DAS 28-CRP) was used for the
evaluation of disease activity in RA patients [16]. The total
number of swollen and tender joints, CRP values, and
patients’ global assessments about disease burden were
recorded on a 0–100 mm visual analog scale. DAS 28-CRP
≤ 2.6 was determined as the mean remission, 2.6–3.2 as
low disease activity, 3.2–5.1 as moderate, and > 5.1 as high
disease activity [16].
2.3. Assessment of TMJ disorders
Panoramic X-ray and lateral panoramic images were
taken for all patients after a detailed and standardized
clinical examination. Evaluation of TMD findings in all
patients was performed by the same doctor (DY) using
the Research Diagnostic Criteria for Temporomandibular
Disorders Axis I (RDC/TMD Axis I). RDC/TMD Axis I is a
symptom-based system that categorizes common subtypes
of TMD according to their physical diagnosis [17,18]. By
RDC/TMD Axis I, patients receive the following group
diagnosis; muscle disorders (group I); disc displacement
(group II); and arthralgia, osteoarthritis, or osteoarthrosis
(group III). Group I (muscle disorders) include any pain
provoked with palpation or opening associated in the
masseter or temporalis muscle. Myofascial pain (Ia)
and myofascial pain with limited opening (Ib) are the
subgroups of muscle disorders. Disc displacement with
reduction (IIa), disc displacement without reduction with
limited opening (IIb), and disc displacement without
reduction without limited opening (IIc) are among the
subgroups of Group II. Group III consists of arthralgia
(IIIa), osteoarthritis with osseous joint changes (IIIb),
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and osteoarthrosis (IIIc). A translation of RDC/TMD
into more than 20 languages is an important factor in the
widespread use of this index in clinical trials [19]. By using
RDC/TMD, we aimed to ensure diagnostic standardization
and increase the knowledge about TMD epidemiology by
making comparisons between different studies.
2.4. Measurement of oxidative stress marker in saliva
To prevent circadian rhythm changes in all patients, a
total of 3 mL unstimulated saliva samples were collected
between 9:00 and 10:00 in the morning and stored at
-80 ° C until analysis of oxidative stress parameters. All
patients were instructed to avoid eating or drinking for
1 hour before sampling. The TAS, TOS levels and ARE
activity were analyzed spectrophotometrically [5,6,20].
The oxidative stress index (OSI), consisting of the ratio of
TOS to TAS, is a crucial marker in this dynamic oxidative
network [12], and the analysis of OSI value was made
using this formula:
OSI (arbitrary unit) = TOS (μmol H2O2 equivalent/L)/
TAS (mmol Trolox equivalent/L) [21,22].
2.5. Statistical analysis
The minimum required sample size has been reckoned
using the G*Power software version 3.1.9.4 (Heinrich
Heine University, Dusseldorf, Germany). A power
analysis was performed based on a previous study [23].
It was estimated that a sample size of 27 participants per
group would be 95% effective in detecting a statistically
significant difference in oxidative biomarker between the
two groups (alpha level = 0.05, effect size = 0.91) [23].
All statistical procedures were evaluated using Statistical
Package for Social Science (v. 20.0 SPSS Inc., Chicago,
IL, USA). Continuous variables were analyzed using
Shapiro–Wilk test for normal distribution. Descriptive
statistics were made for some of the data and the results
were given as frequency, mean ± standard deviation (SD),
minimum and maximum values. An independent sample
t-test was used for comparison of the parametric variables.
Categorical data were interpreted with the chi-square test.
Categorical variables were summarized as counts and
percentages. Univariate linear regression models were used
to assess the relationship between parameters. The p-value
for statistical significance was accepted as < 0.05.
3. Results
Thirty patients in the RA group (25 females, 5 males; mean
age: 42.62 ± 10.89 years) and 30 patients in the control
group (25 females, 5 males; mean age: 42.62 ± 10.89 years)
were included in this study and the collected data was
analyzed between RA and control groups. The effect of sex
and age on the RDC/TMD Axis I diagnosis was analyzed
and it was found to not be statistically significant (for age
RA and control group: p = 0.236, p = 0.381; for sex RA and
control group, p = 0.598, p = 0.140).

3.1. Analysis of clinical parameters
Clinical characteristics of patients with RA were shown
in Table 1. The total follow-up period of patients with RA
was 4.97 years. Disease activity in RA patients was assessed
by DAS 28-CRP, of which 60% were in remission/low
activity and 40% in moderate/high activity. The majority
of patients were using csDMARDs (90%) and GCs (70%).
Diabetes mellitus (3.3%), hypertension (6.7%), and
secondary Sjogren’s syndrome (3.3%) were prevalent comorbid disorders observed in RA patients in the study.
3.2. Analysis of clinic and radiographic TMJ involvement
According to RDC/TMD Axis I, nine RA patients were
diagnosed with myofascial pain (Group Ia), and only 3 RA
patients presented disc displacement (Group II). Finally,
18 RA patients were diagnosed with osteoarthritis (Group
IIIb). In the control group, 21 patients were in Group
Ia, and only 1 patient presented disc displacement and 8
patients were in Group IIIb.
The results from the radiographic changes in the
temporomandibular joint (TMJ) showed that RA

Table 1. Clinical characteristics of patients with rheumatoid
arthritis.
Variable

n = 30

Total follow-up (year) [mean (min-max)] 4.97 (0.10–16.0)
CRP [mean (min-max)]

10.78 (0.20–51.00)

ESR [mean (min-max)]

29.53 (8.00–56.00)

DAS 28-CRP [mean (min-max)]

3.05 (1.30–6.20)

DAS 28-CRP < 3.2 (%)

60

DAS28-CRP > 3.2 (%)

40

RF positivity (%)

43.3

ACPA positivity (%)

56.7

Current treatment
csDMARD (%)

90.0

GC (%)

70.0

bDMARD (%)

20.0

Comorbidities
Diabetes mellitus (%)

3.3

Hypertension (%)

6.7

Secondary Sjögren’s syndrome (%)

3.3

Others (%)

13.3

C-reactive protein (CRP), the erythrocyte sedimentation rate
(ESR), disease activity score 28-C reactive protein (DAS 28CRP), rheumatoid factor (RF), anticitrullinated protein antibody
(ACPA), disease modifying antirheumatic drugs (DMARD),
conventional DMARD (csDMARD), biologic DMARD
(bDMARD), glucocorticoid (GC), number (n).
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patients had flattening on the condylar head (13.3%),
osteophyte formation (10%), condylar erosion (33.3%),
and subchondral sclerosis (6.7%). In the control group,
there was flattening on the condylar head (6.7%),
osteophyte formation (13.3%), and condylar erosion, and
subchondral sclerosis (3.3%). A substantial distinction was
detected between groups in terms of radiographic changes
in TMJ (p = 0.016 right TMJ; p = 0.022 left TMJ; Table
2). Condylar erosion was more frequent in the RA group
compared to the controls.
When the relevance between disease activity and TMJ
involvement was evaluated, the effect of DAS 28-CRP
scores on the presence of the radiographic change in TMJ
was found to be insignificant (p = 0.266).
3.3. Evaluation of denture quality
There was a significant distinction in the number of missing
teeth between groups (p = 0.010, Table 3). The number of
teeth remaining was higher in the control group and the
result was eloquent (p = 0.005, Table 3). The numbers of
decayed, filled, root canal-treated teeth and teeth with
periapical lesions were compared and no significant results
were found between the groups (p > 0.05). Those who use
dentures were mostly in RA patients and this relation was
found to be meaningful (p = 0.025, Table 3).
3.4. Analysis of oxidative stress biomarkers
While no significant difference was found between
ARE activity and TOS levels (p = 0.921 and p = 0.243,
respectively), there was a significant distinction in the
comparison of TAS and OSI levels between the groups (p =
0.013; p = 0.029, respectively, Table 4). When RA patients
were categorized into two groups according to DAS 28CRP score (below 3.2 and above 3.2) in terms of the activity
of the disease, no significant distinction was observed

between TAS, TOS levels and ARE activity of both groups
(p = 0.508, p = 0.163, and p = 0.955, respectively).
Table 5 shows the effect of age, drugs, disease duration,
and DAS 28-CRP score on oxidant/antioxidant status.
According to univariate linear regression analysis, the
effect of related parameters on ARE, TOS, TAS dependent
variables was insignificant.
RA patients were classified according to the duration
of the disease. Disease period of ≤3 years were compared
those with longer than 3 years [15]. Comparison of
oxidative stress and radiographic changes according to
the RA disease duration ≤ 3years and >3 years revealed no
significant difference.
4. Discussion
RA is an inflammatory autoimmune disorder characterized
by synovial proliferation, bone destruction, and cartilage
degradation. Although the etiology of RA is still unclear,
recent studies draw attention to the role of reactive oxygen
species in the pathogenesis of the disease. Besides, RA
patients have a higher cumulative risk of TMD than the
control group, and TMJ symptoms constantly emerged
in the early stages of RA [24,25]. The majority of RArelated TMD patients developed symptoms before or
shortly within 1 year of the involvement of other body
joints [5,24]. In this study, the total follow-up period of
patients with RA was 4.97 years and more than half of RA
patients belonged to Group IIIb (osteoarthritis). Since the
RA history of the patients in our study group is long-term,
TMJ findings may be common. Similar to previous studies
[26,27], we observed that condylar erosion was the most
common pathology in RA with a rate of 33.3% on both
sides. The connective tissue degeneration, inflammatory,
and degenerative changes of TMJ can be more aggressive

Table 2. Panoramic radiography findings of rheumatoid arthritis (RA) patients and controls.

Right TMJ

Left TMJ

Radiographic changes
in TMJ

RA
(n = 30)

Control
(n = 30)

Normal

11 (36.7%)

22 (73.3%)

Flattening

4 (13.3%)

2 (6.7%)

Osteophyte

3 (10.0%)

4 (13.3%)

Condylar erosion

10 (33.3%) *

1 (3.3%) *

Subchondral sclerosis

2 (6.7%)

1 (3.3%)

Normal

10 (36.7%)

Flattening

7 (13.3%)

3 (6.7%)

Osteophyte

4 (10.0%)

3 (13.3%)

Condylar erosion

8 (33.3%) *

1 (3.3%) *

Subchondral sclerosis

1 (6.7%)

2 (3.3%)

number (n), temporomandibular joint (TMJ).
* indicates significant difference between RA and control groups.
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p* value

0.016

21 (73.3%)*
0.022

YAMAN et al. / Turk J Med Sci
Table 3. Dental findings of the participants.
Rheumatoid arthritis

Control

p* value

The number of teeth remaining (mean ± SD)

22.50 ± 7.065

26.77 ± 3.748

0.005*

The number of missing teeth (mean ± SD)

8.87 ± 7.510

4.70 ± 4.162

0.010*

The number of filled teeth (mean ± SD)

1.87 ± 2.897

2.90 ± 3.111

0.188

The number of root canal treated teeth (mean ± SD)

0.93 ± 1.574

2.00 ± 2.560

0.057

The number of decayed teeth (mean ± SD)

1.37 ± 2.327

1.80 ± 1.955

0.438

The number of teeth with periapical lesions (mean ± SD)

0.47 ± 0.937

0.37 ± 0.850

0.667

No dentures (n)

12

23

0.025*

Removable denture (n)

9

1

Fixed denture (n)

7

5

Total and partial dentures (n)

1

0

Fixed and partial dentures (n)

1

1

number (n), standard deviation (SD).
*The p-value for statistical significance was accepted as < 0.05.
Table 4. Comparison of salivary oxidative stress biomarkers between groups.
Rheumatoid arthritis
(mean ± SD)

Control
(mean ± SD)

p* value

TAS, mmol/L

0.57 ± 0.25

0.72 ± 0.18

0.013

TOS, µmol/L

14.12 ± 25.37

3.75 ± 1.63

0.243

OSI

2.12 ± 3.15

0.54 ± 0.28

0.029

ARE, U/L

314.20 ± 29.75

318.60 ± 11.44

0.921

Total antioxidant status (TAS), total oxidant status (TOS), arylesterase (ARE), oxidative
stress index (OSI), standard deviation (SD).

and develop faster in RA. However, drugs in RA can
control pain, patients may ignore the self-awareness
of TMJ problems [28]. The high incidence of condylar
erosion can be attributed to this.
Grevers et al. declared that 20% of RA patients suffer
from secondary Sjogren’s syndrome [29]. However, our
study showed that secondary Sjogren’s syndrome was
accompanied by fewer of the patients (3.3%) with RA.
This may be because the size of our study population is
less than the previous study. Although the salivary glands
are remarkably affected in RA, no recent studies are
analyzing the antioxidant profile of the salivary secretion
of these patients. Hence, the main strength of this study is
to research the correlation of biomarkers associated with
oxidative stress as well as TMD symptoms and intraoral
findings in both groups.
ARE is an important member of the antioxidant defence
system which is reduced in autoimmune diseases [30,31].
Altındağ et al. also reported that the serum ARE activity

was lower in RA patients than in the controls [32]. Işık et al.
reported that serum ARE activity (359.82 ± 48.94 U/L) in RA
patients was significantly lower (393.55 ± 42.27 U/L) than
controls [14]. In this study, salivary ARE activity was found
as 314.20 ± 29.75 U/L in the RA group and 318.60 ± 11.44
U/L in the control group. Similarly, we observed lower ARE
activity in patients with RA than in controls, although this
difference was not significant. In this study, the significant
high OSI level in the RA group indicates that the TOS level is
high and early proactive intervention is required. A significant
association between salivary oxidative stress biomarkers with
increased oxidative stress products and TMD pain has been
previously reported in TMD patients [33].
In the present study, the mean TAS value was found to
be lower in RA patients (0.57 ± 0.25 (mmol/L) than in the
control group (0.72 ± 0.18 mmol/L) (p = 0.013). Nagler
et al. stated higher TAS levels for RA patients as 2.17
(mmol/L) than controls as 1.10 (mmol/L) [10]. Almeida
et al. reported mean TAS level lower in TMD patients as
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Table 5. The effect of age, drugs, disease duration, and DAS 28-CRP score on oxidant/
antioxidant status.
Univariate model

Parameters

TAS

TOS

ARE

B (95.0% confidence interval)

p* value

bDMARD

–0.127 (–0.369 to 0.115)

0.291

GC

–0.105 (–0.316 to 0.107)

0.319

Total follow-up (year)

–0.010 (–0.034 to 0.013)

0,366

Age

–0.003 –0.012 to 0.007)

0.578

DAS 28-CRP

–0.006 (–0.207 to 0.196)

0.955

bDMARD

17.923 (–5.202 to 41.048)

0.124

GC

3.778 (–24.801 to 17.245)

0.716

Total follow-up (year)

0.544 (–1.758 to 2.845)

0.632

Age

0.214 (–0.684 to 1.112)

0.629

DAS 28-CRP

–6.400 (–25.957 to 13.157)

0.508

bDMARD

7.667 (–20.493 to 35.826)

0.581

GC

–9.397 (–33.843 to 15.050)

0.438

Total follow-up (year)

0.066 (–2.644 to 2.777)

0.960

Age

0.295 (-0.756 to 1.347)

0.570

DAS 28-CRP

–15.611 (–37.927 to 6.704)

0.163

Disease modifying antirheumatic drugs (DMARD), conventional DMARD (csDMARD),
biologic DMARD (bDMARD), glucocorticoid (GC), disease activity score 28-C reactive
protein (DAS 28-CRP), total antioxidant status (TAS), total oxidant status (TOS), arylesterase
(ARE), oxidative stress index (OSI).

0.13 (mmol/L) than in controls as 0.264 (mmol/L) [34].
Similarly, some previous studies gave TAS levels lower in
RA or TMD patients [35,36]. Our study also supports the
results showing that biomarkers associated with oxidative
stress are substantial in the etiology of diseases in the
maxillofacial region [14,33].
Several clinical studies suggest a possible association
between periodontitis/tooth loss and RA [37,38]. Similarly,
in these studies, patients with RA had more missing teeth
than controls. Also, a significantly higher prosthesis usage
point outs the importance of the periodontal status of
patients with RA. Over the last decades, the investigators
emphasized the importance of oxidative and inflammatory
imbalance in patients with poor periodontal health [39,40].
In this study, TMJ damage and osteoarthritic changes have
occurred even if the fixed or removable partial denture
usage and these treatment applications have no preventive
or therapeutic effectiveness on TMD similar to previous
studies [41,42].
The limitation of this study was related to the small
sample size. Also, the majority of the participants with
TMD were females, as stated in the literature [43]. In order
to generalize and confirm these results, studies involving
more participants are required.
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This study is the first to show ARE activity in the saliva
of patients with RA and controls. Diminished TAS levels
and increased OSI levels were observed in RA patients
compared to controls. However, a similarly significant
relationship could not be observed at the ARE activity.
Besides, disease activity has not a prominent impact on the
salivary oxidative stress status of RA patients. Degenerative
changes in TMJ can be more aggressive in RA. However,
with drugs that control pain in patients with RA, TMJ
problems may be overlooked. All these results show the
importance of clinical examination and close monitoring
for effective detection and early treatment of TMD in RA
patients.
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